Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to 0.19%.

  • CytomX Therapeutics' Return on Capital Employed fell 400.0% to 0.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.33% for FY2024, which is 4200.0% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Return on Capital Employed stood at 0.19%, which was down 400.0% from 0.44% recorded in Q2 2025.
  • CytomX Therapeutics' Return on Capital Employed's 5-year high stood at 0.61% during Q1 2025, with a 5-year trough of 1.11% in Q4 2022.
  • Its 5-year average for Return on Capital Employed is 0.21%, with a median of 0.28% in 2021.
  • In the last 5 years, CytomX Therapeutics' Return on Capital Employed plummeted by -7300bps in 2022 and then surged by 10000bps in 2023.
  • CytomX Therapeutics' Return on Capital Employed (Quarter) stood at 0.42% in 2021, then crashed by -166bps to 1.11% in 2022, then soared by 90bps to 0.12% in 2023, then skyrocketed by 587bps to 0.57% in 2024, then crashed by -67bps to 0.19% in 2025.
  • Its last three reported values are 0.19% in Q3 2025, 0.44% for Q2 2025, and 0.61% during Q1 2025.